重组人脑利钠肽联合连续性肾脏替代治疗心肾综合征难治性心力衰竭观察

摘要

Objective:To observe the clinical efficacy of rh-BNP combined with continuous renal replacement therapy on the re-fractory heart failure in cardiorenal syndrome. Methods:Totally 48 patients with refractory heart failure in cardiorenal syndrome in our hospital were selected and randomly divided into the observation group and the control group. The control group was received the con-ventional drug therapy combined with continuous renal replacement therapy, and the observation group was received rh-BNP therapy ad-ditionally. After 7 days, NT-ProBNP, heart rate, LVEF, SV, BUN, Scr and GFR of the two groups were compared, and the clinical efficacy of the two groups was evaluated. Results:After the treatment, all the observed indicators in the two groups were significantly improved than those before the treatment, and the improvement in the observation group was better than that in the control group ( P<0. 05). The total effective rate of the observation group was higher than that of the control group(91. 67% vs 79. 17%, P<0. 05). Conclusion:The combination of rh-BNP and continuous renal replacement therapy can improve heart and kidney function of the refrac-tory heart failure in cardiorenal syndrome with better efficacy.%目的：：观察重组人脑利钠肽联合连续性肾脏替代治疗心肾综合征难治性心力衰竭的临床疗效。方法：48例心肾综合征难治性心力衰竭患者随机分为观察组及对照组各24例。对照组给予常规药物治疗及连续性肾脏替代治疗,观察组在对照组基础上联合重组人脑利钠肽治疗。治疗7 d后对比两组患者血清N端B型尿钠肽前体( NT-ProBNP)、心率、超声心动图左室射血分数( LVEF)、每搏输出量( SV)、血清尿素氮( BUN)、肌酐( Scr),肾小球滤过率( GFR)等指标,评价两组的临床疗效。结果：治疗后两组患者各项观察指标较治疗前均有明显改善(P<0.05),且观察组治疗后各指标均优于对照组(P<0.05)。观察组总有效率明显高于对照组(91.67% vs 79.17%,P<0.05)。结论：联合使用重组人脑利钠肽及连续性肾脏替代治疗能够更好的改善心肾综合征难治性心力衰竭患者的心肾功能,提高临床疗效。